Optimization of Antischistosomal Chemotypes
Project Abstract
The long-term goal of this proposal is to discover a new orally active single-dose antischistosomal drug. The objective of this proposal is to identify one or more antischistosomal drug development candidates. To accomplish this objective, we will optimize four promising and structurally diverse antischistosomal chemotypes – ozonides , indole sulfonamides, azonine keto lactams, and aminopyrazinamides and define the host-mediated mode of action of aryl hydantoin drug development candidate AR102. The expected outcome from this work is to identify one or more antischistosomal drug development candidates effective against all parasite stages and with a novel mechanism of action. Such a drug would be important in the chemotherapy of drug-resistant schistosomiasis and likely be valuable in integrated control programs to curb this parasitic disease.
